Biomarker and testing questions
Ask whether BRCA1, BRCA2, HRD, germline, or tumor testing is relevant.
Second-opinion questions
Should genetic counseling, tumor testing, or family-risk questions be discussed before deciding?
Safety discussion reminder
PARP inhibitors require monitoring and drug-specific safety review.
Official source links
- NCI cancer drug information (NCI)
- DailyMed label search (DailyMed)
- FDA label search (FDA)
- ClinicalTrials.gov search (ClinicalTrials.gov)